These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 15101461)
1. What's new in clinical pharmacology and therapeutics. Chawla PS; Kochar MS WMJ; 2004; 103(1):13-9. PubMed ID: 15101461 [TBL] [Abstract][Full Text] [Related]
2. What's new in ... clinical pharmacology and therapeutics. Kochar MS; Campbell WB Wis Med J; 1996 Sep; 95(9):645-6. PubMed ID: 8855713 [No Abstract] [Full Text] [Related]
3. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. Reichert JM; Paquette C Curr Opin Mol Ther; 2003 Apr; 5(2):139-47. PubMed ID: 12772503 [TBL] [Abstract][Full Text] [Related]
4. The approval of mifepristone (RU486) in the United States: What's wrong with this picture? Blumenthal P; Johnson J; Stewart F Medscape Womens Health; 2000; 5(4):E7. PubMed ID: 11109052 [No Abstract] [Full Text] [Related]
5. What's in the pipeline. Glazer WM Behav Healthc; 2007 Dec; 27(12):19-21. PubMed ID: 18429587 [No Abstract] [Full Text] [Related]
7. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808 [TBL] [Abstract][Full Text] [Related]
8. The food and drug administration and molecular imaging agents: potential challenges and opportunities. Henderson JA; Alexander BC; Smith JJ J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943 [TBL] [Abstract][Full Text] [Related]
10. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II. Giacoia GP; Mattison DR Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307 [TBL] [Abstract][Full Text] [Related]
11. New Drugs 98. Part III. Hussar DA Nursing; 1998 Jun; 28(6):41-5; quiz 46. PubMed ID: 9668790 [No Abstract] [Full Text] [Related]
12. Antiangiogenic therapy for cancer: an update. Shojaei F; Ferrara N Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969 [TBL] [Abstract][Full Text] [Related]
13. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
14. Are novel drugs more risky for patients than less novel drugs? Olson MK J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240 [TBL] [Abstract][Full Text] [Related]
15. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency. Schultheis LW; Rappaport BA Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189 [No Abstract] [Full Text] [Related]
16. Food and Drug Administration approval process for ophthalmic drugs in the US. Lloyd R; Harris J; Wadhwa S; Chambers W Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492 [TBL] [Abstract][Full Text] [Related]
17. What's the problem with generic antiepileptic drugs?: a call to action. Berg MJ Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211 [No Abstract] [Full Text] [Related]
18. FDA new drug approvals in 2007. Wynn RL Gen Dent; 2008; 56(6):506-10. PubMed ID: 18810906 [No Abstract] [Full Text] [Related]
19. FDA new drug approvals in 2005. Wynn RL Gen Dent; 2006; 54(4):230-3. PubMed ID: 16903192 [No Abstract] [Full Text] [Related]
20. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes. Misbin RI Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753 [No Abstract] [Full Text] [Related] [Next] [New Search]